Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The launch of generic liraglutide (Teva, August 2025) and anticipated oral GLP-1 options (oral Wegovy approved December 2025, orforglipron pending) offer lower-cost alternatives that may simplify pharmacy benefit management
IV therapy is a tool, not a cure-all
An initial analysis of the FDA adverse event reporting system (FAERS) data demonstrated no consistent trends in DKA with SGLT2i use over time [39], however an alternative cohort study of 50,220 individuals with type 2 diabetes showed the highest risk of DKA shortly after SGLT2i initiation, which subsequently reduced with time [40]
It helps convert carbohydrates into glucose, providing a steady energy source throughout the day
US$ 28.83
US$ 20.73
US$ 23.97
US$ 25.95
